Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company announced it has resubmitted its New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara®), a brain cancer imaging candidate. Telix’s resubmission includes new data addressing the FDA’s previous requests and could bring the first FDA-approved targeted PET agent for adult and paediatric brain cancer imaging to the U.S. market.

What did Telix Pharmaceuticals report?

• Resubmitted NDA for TLX101-Px (Pixclara®) brain cancer imaging agent to U.S. FDA
• Submission includes additional data and statistical analysis to address FDA’s Complete Response Letter
• TLX101-Px has Orphan Drug and Fast Track designations from the FDA
• No FDA‑approved targeted amino acid PET agent currently available for brain cancer imaging in the U.S.
• TLX101-Px is intended for both adult and paediatric glioma imaging

What else do investors need to know?

TLX101-Px is being developed to help doctors distinguish between recurrent or progressing glioma and changes caused by prior treatments. This could make a real difference for patients struggling with brain cancer by helping their clinical teams make better informed decisions.

Globally, PET imaging with 18F-FET (the basis for TLX101-Px) is part of clinical guidelines, but no similar FDA-approved product exists in the U.S. The agent targets LAT1 and LAT2 transport proteins and also has potential as a companion diagnostic for Telix’s investigational brain cancer therapy, TLX101-Tx.

Telix has operations spanning the U.S., Europe, Japan, and other countries, and is headquartered here in Melbourne. Its Illuccix® imaging agent is already approved in multiple markets. However, both TLX101-Px and the therapy TLX101-Tx are investigational and not yet approved anywhere.

What did Telix Pharmaceuticals management say?

Dr. David N. Cade, Telix Group Chief Medical Officer, said:

We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.

What’s next for Telix Pharmaceuticals?

Telix expects the FDA review process to progress in the coming months after its resubmission. With Orphan Drug and Fast Track status, the company could potentially see an expedited pathway to approval, if the regulator is satisfied with the new data.

In the meantime, Telix continues work on its broader pipeline, including further development of both imaging and therapeutic products for cancer and rare diseases worldwide. Investors will be watching for updates on FDA timelines and any developments in the pivotal study of TLX101-Tx.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 59%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 10% over the same period.

View Original Announcement

The post Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent appeared first on The Motley Fool Australia.

More reading

• Orica settles US litigation and announces US acquisition
• Lynas Rare Earths announces US$96m US rare earth agreement
• Meridian Energy: February 2026 update shows growth and strong storage
• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.